Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,396 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma.
Ohara M, Suda G, Kohya R, Sasaki T, Yoda T, Yoshida S, Fu Q, Yang Z, Hosoda S, Maehara O, Ohnishi S, Tokuchi Y, Kitagataya T, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Ogawa K, Sakamoto N. Ohara M, et al. Among authors: sasaki t. Front Nutr. 2023 Oct 6;10:1272728. doi: 10.3389/fnut.2023.1272728. eCollection 2023. Front Nutr. 2023. PMID: 37867493 Free PMC article.
Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
Umemura M, Suda G, Tsukamoto S, Ebata K, Takahash S, Sasaki T, Nakajima S, Hirata K, Ozasa M, Takano M, Katagiri M, Sakamoto N. Umemura M, et al. Among authors: sasaki t. BMC Infect Dis. 2021 Apr 27;21(1):389. doi: 10.1186/s12879-021-06091-x. BMC Infect Dis. 2021. PMID: 33906643 Free PMC article.
Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma.
Yang Z, Suda G, Maehara O, Ohara M, Yoda T, Sasaki T, Kohya R, Yoshida S, Hosoda S, Tokuchi Y, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Ogawa K, Ohnishi S, Sakamoto N. Yang Z, et al. Among authors: sasaki t. Cancers (Basel). 2023 Jan 18;15(3):593. doi: 10.3390/cancers15030593. Cancers (Basel). 2023. PMID: 36765554 Free PMC article.
Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight.
Tokuchi Y, Suda G, Kawagishi N, Ohara M, Kohya R, Sasaki T, Yoda T, Maehara O, Ohnishi S, Kubo A, Yoshida S, Fu Q, Yang Z, Hosoda S, Kitagataya T, Suzuki K, Nakai M, Sho T, Natsuizaka M, Ogawa K, Sakamoto N. Tokuchi Y, et al. Among authors: sasaki t. Hepatol Res. 2023 Jul;53(7):595-606. doi: 10.1111/hepr.13899. Epub 2023 Apr 4. Hepatol Res. 2023. PMID: 36945790
Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma.
Kohya R, Suda G, Ohara M, Sasaki T, Yoda T, Sakurai N, Yoshida S, Fu Q, Yang Z, Hosoda S, Maehara O, Ohnishi S, Tokuchi Y, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Ogawa K, Sakamoto N. Kohya R, et al. Among authors: sasaki t. Cancers (Basel). 2023 Jun 20;15(12):3257. doi: 10.3390/cancers15123257. Cancers (Basel). 2023. PMID: 37370867 Free PMC article.
Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.
Sho T, Suda G, Ohara M, Kohya R, Sasaki T, Yoshida S, Hosoda S, Ogawa K, Kitagataya T, Maehara O, Ohnishi S, Kawagishi N, Natsuizaka M, Nakai M, Baba M, Yamamoto Y, Tsukuda Y, Meguro T, Yamada R, Kobayashi T, Takagi T, Sakamoto N; NORTE STUDY GROUP. Sho T, et al. Among authors: sasaki t. Target Oncol. 2024 Sep;19(5):769-778. doi: 10.1007/s11523-024-01092-7. Epub 2024 Sep 2. Target Oncol. 2024. PMID: 39222223
Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCC.
Yasuura N, Suda G, Ohara M, Meno A, Sho T, Kohya R, Sasaki T, Yoda T, Yoshida S, Fu Q, Yang Z, Hosoda S, Maehara O, Ohnishi S, Saitou T, Sugiyama M, Fukuhara T, Baba M, Kitagataya T, Kawagishi N, Nakai M, Natsuizaka M, Ogawa K, Taketomi A, Sakamoto N. Yasuura N, et al. Among authors: sasaki t. Aliment Pharmacol Ther. 2024 Nov;60(10):1315-1324. doi: 10.1111/apt.18229. Epub 2024 Sep 4. Aliment Pharmacol Ther. 2024. PMID: 39228289
Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective study.
Yang Z, Suda G, Sho T, Maehara O, Ohara M, Yoda T, Fu Q, Sasaki T, Kohya R, Yoshida S, Hosoda S, Kitagataya T, Kawagishi N, Nakai M, Natsuizaka M, Ogawa K, Ohnishi S, Yamamoto Y, Baba M, Yamada R, Kobayashi T, Chen M, Sakamoto N; NORTE Study Group. Yang Z, et al. Among authors: sasaki t. Hepatol Res. 2024 Nov 25. doi: 10.1111/hepr.14139. Online ahead of print. Hepatol Res. 2024. PMID: 39584803
9,396 results